Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.
Publication/Presentation Date
2-1-2009
Abstract
Alemtuzumab has been used in off-label studies of solid organ transplantation. We extend our report of the first 200 consecutive living donor solitary kidney transplantations under alemtuzumab pretreatment with tacrolimus monotherapy and subsequent spaced weaning to 3 years of follow-up. We focused especially on the causes of recipient death and graft loss, and the characteristics of rejection. The actuarial 1-, 2- and 3-year patient and graft survivals were 99.0% and 98.0%, 96.4% and 90.8% and 93.3% and 86.3%, respectively. The cumulative incidence of acute cellular rejection (ACR) at the following months was 2%
Volume
9
Issue
2
First Page
355
Last Page
366
ISSN
1600-6143
Published In/Presented At
Tan, H. P., Donaldson, J., Basu, A., Unruh, M., Randhawa, P., Sharma, V., Morgan, C., McCauley, J., Wu, C., Shah, N., Zeevi, A., & Shapiro, R. (2009). Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 9(2), 355–366. https://doi.org/10.1111/j.1600-6143.2008.02492.x
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
19120078
Department(s)
Administration and Leadership
Document Type
Article